Accessibility Menu
Amphastar Pharmaceuticals Stock Quote

Amphastar Pharmaceuticals (NASDAQ: AMPH)

$24.27
(2.3%)
+0.54
Price as of October 21, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$24.26
Daily Change
(2.3%) +$0.54
Day's Range
$23.73 - $24.38
Previous Close
$24.26
Open
$23.73
Beta
0.57
Volume
5
Average Volume
491,564
Market Cap
1.1B
Market Cap / Employee
$24.26M
52wk Range
$20.39 - $53.96
Revenue
-
Gross Margin
0.48%
Dividend Yield
N/A
EPS
$2.67
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Amphastar Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
AMPH-52.26%+17.82%+3.33%+142%
S&P+15.06%+95.03%+14.29%+244%

Amphastar Pharmaceuticals Company Info

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$174.41M-4.4%
Gross Profit$82.50M-10.4%
Gross Margin47.30%-3.2%
Market Cap$1.08B-44.7%
Market Cap / Employee$0.53M0.0%
Employees2K15.2%
Net Income$31.03M-18.2%
EBITDA$58.42M-15.8%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$187.92M-1.0%
Accounts Receivable$132.98M1.2%
Inventory191.756.6%

Liabilities

Q2 2025YOY Change
Long Term Debt$646.69M4.9%
Short Term Debt$8.81M107.4%

Ratios

Q2 2025YOY Change
Return On Assets8.67%-2.9%
Return On Invested Capital9.77%0.1%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$25.03M-60.3%
Operating Free Cash Flow$35.59M-48.5%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Earnings16.1512.1210.528.60-32.55%
Price to Book3.232.471.891.46-49.86%
Price to Sales3.482.601.981.53-47.64%
Price to Tangible Book Value17.6713.529.756.56-78.06%
Price to Free Cash Flow TTM14.7911.059.639.85-15.72%
Enterprise Value to EBITDA40.4838.9835.4226.13-27.00%
Free Cash Flow Yield6.8%9.0%10.4%10.2%18.66%
Return on Equity23.8%23.3%19.9%18.3%-28.36%
Total Debt$629.85M$650.55M$652.53M$655.50M5.63%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.